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and B cell hyperresponsiveness (Mohan et al., 1998).
When combined with Sle2 and Sle3 congenic C57BL/6
strains, fatal autoimmune glomerulonephritis is ob-
served (Mohan et al., 1999). The contribution of genetic
backgrounds to the emergence of autoimmunity for
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these susceptible strains is best characterized for MHC
locus contribution to autoimmunity (McDevitt, 1998;
Summary Vyse et al., 1998; Ibnou-Zekri et al., 1999). In NOD, for
example, a specific MHC locus is required for disease
By virtue of its ability to couple the BCR to an inhibitory development. Similarly, induced arthritis in the collagen
pathway, FcgRIIB can potentially determine the fate immunization models require H-2q,r backgrounds to
of B cells upon IgG immune complex engagement. We break tolerance and trigger autoantibodies and arthritis
now provide evidence for FcgRIIB as a component of (Wooley et al., 1981). Recently, the role of another class
of genetic modifiers has been described, the inhibitorya peripheral tolerance pathway with the observation
receptors of the ITIM class, including CD22, FcgRIIB,that RIIB2/2 mice develop autoantibodies and autoim-
and PD-1 and their signaling molecules Lyn, SHP-1, andmune glomerulonephritis in a strain-dependent fash-
SHIP (Hibbs et al., 1995; Shultz et al., 1997; Nishimuraion. Transfer of the autoimmune phenotype is associ-
et al., 1999; O'Keefe et al., 1999). Deficiencies of theseated with the presence of donor RIIB2/2 B cells, with
genes can lead to the loss of tolerance and emergencethe RIIB1/1 myeloid cells primarily derived from the
of autoimmunity. These results suggest that the balancerecipient. These results suggest that deficiency of RIIB
between activation and inhibitory signaling pathwayson B cells leads to autoimmune disease in specific
is critical in maintaining tolerance and preventing the
genetic backgrounds, thus identifying it as a suscepti- emergence of autoimmune disease.
bility factor under the influence of epistatic modifiers Fc receptors for IgGs are paradigms for the pairing
for the development of autoimmunity. of activation/inhibition membrane receptors that func-
tion by transducing opposing signals upon ligation by
a common ligand, in this case the IgG immune complexIntroduction
(Ravetch and Kinet, 1991). FcgRIII activates cellular re-
sponses through its ITAM motif, sequentially recruitingSystemic autoimmune diseases, like lupus, arise as a
Src and Syk tyrosine kinases, leading to the activationconsequence of the failure of multiple immunological
of PI3K and subsequent activation of PIP3-dependentmechanisms (Theofilopoulos, 1995; Kotzin, 1996; Vyse
Tec kinases and PLCg. These signals culminate in theand Todd, 1996; Harley et al., 1998). Loss of tolerance
release of intracellular calcium and influx of extracellularto nuclear antigens with the emergence of autoreac-
calcium to generate a sustained activation responsetive lymphocytes initiates the process of autoantibody
(Weiss and Littman, 1994). Opposing these activationproduction. Continued stimulation of these autoantibody-
signals is the inhibitory receptor FcgRIIB, which con-producing cells leads to significant autoantibody accu-
tains an ITIM motif (Bolland and Ravetch, 1999). Upon itsmulation, with the resulting formation of immune com-
coligation to an ITAM-bearing receptor, FcgRIIB recruitsplexes. Deposition of these complexes in terminal organs,
the inositol phosphatase SHIP to its ITIM motif, hydrolyz-like the kidney, trigger inflammatory responses by ef-
ing PIP3 and preventing further activation of Tec kinasesfector cells, culminating in tissue destruction and patho-
and PLCg (Ono et al., 1996, 1997; Bolland et al., 1998).logical manifestations of disease. Genetic and environ-
FcgRIIB thus acts to set thresholds for immune complexmental factors contribute to individual susceptibility to
activation of B and myeloid cells. In addition to thisthe development of autoimmune disease. Dissection of
inhibitory activity, FcgRIIB, upon self-ligation, inducesthese susceptibility factors is a major focus of research
apoptosis in B lymphocytes, potentially contributing toin autoimmune diseases and has been greatly facilitated
the maintenance of tolerance during affinity maturationby the characterization of animal models of disease.
by promoting the deletion of low-affinity, self-reactiveThe role of epistatic modifiers in autoimmune disease
lymphocytes from the germinal center (Pearse et al.,is illustrated, for example, by the characterization of
1999). Both activation and inhibitory FcgRs are able toautoimmune models such as MRL/lpr, NOD, and NZB/
modify the development or progression of autoimmuneNZW (Drake et al., 1995; Wicker et al., 1995; Vidal et al.,
disease by influencing either B cell responsiveness or1998; Wakeland et al., 1999).
myeloid cell activation. These pathways function inde-Genetic dissection of these autoimmune-prone strains
pendently of perturbations in the T cell response, since
has begun to identify components that contribute to T cells do not express either activation or inhibitory
disease initiation and progression. For example, three FcgRs. Activation FcgRs are required to couple cyto-
loci derived from NZW (Sle1, 2, and 3) have been identi- toxic antibodies or immune complexes to effector cells,
fied that contribute to development of lupus in the B/W thereby triggering tissue damage (Clynes and Ravetch,
model (Morel et al., 1997). When transferred to the 1995; Clynes et al., 1999). Deletion of the activation
C57BL/6 background, the Sle1 interval from chromo- FcgRs protects mice from antibody-mediated spontane-
some 1 triggers the loss of tolerance to nuclear antigens ous or induced autoimmune disease without altering the
expression of autoantibodies (Clynes et al., 1998). In
contrast, the inhibitory FcgRIIB normally functions to* To whom correspondence should be addressed (e-mail: ravetch@
rockefeller.edu). restrict myeloid cell responsiveness and potentially to
Immunity
278
limit the activation of low-affinity, autoreactive B cells.
Deficiency of FcgRIIB results in elevated serum IgG lev-
els in response to immunization and renders mice sus-
ceptible to induced autoimmune disease, as in the case
of collagen-induced arthritis and Goodpasture's syn-
drome (Takai et al., 1996; Yuasa et al., 1999; Nakamura
et al., 2000). Immunization of FcgRIIB mice of the non-
permissive H-2b haplotype with bovine type II collagen
results in the appearance of collagen-induced arthritis
(Yuasa et al., 1999). Similarly, immunization of FcgRIIB-
deficient mice with bovine type IV collagen results in
the appearance of murine anti-type IV collagen antibod-
ies with onset of diffuse pulmonary hemorrhage, IC de-
position in glomeruli, and renal failure in a pattern that
mimics Goodpasture's syndrome (Nakamura et al.,
2000). While these studies indicated that FcgRs are able
to modify the effector arm of autoimmune disease, direct
evidence for their role in initiation of spontaneous loss
of tolerance to self-antigens and development of auto-
immunity was lacking.
In order to facilitate the dissection of the complex
interactions between pathways which culminate in auto-
immunity, we have developed an animal model of spon-
taneous lupus that displays strain-specific epistasis. In
this model, deficiency of the inhibitory IgG Fc receptor,
FcgRIIB, results in anti-dsDNA and anti-chromatin anti-
bodies when present on the C57BL/6 background.
These mice develop fatal autoimmune glomerulonephri- Figure 1. Decreased Life Expectancy of RII2/2B6 Mice
tis and have a mean survival of 9 months. In contrast, (A) Forty-five RIIB2/2B6 (N7) and 35 RIIB2/2BALB/c (N12) mice were
BALB/c mice deficient in RIIB maintain tolerance to nu- followed to calculate the cumulative proportion of dead animals at
clear antigens and are resistant to the development of each age. Values are plotted as the cumulative mortality of the
population at any given month.autoimmunity. The mechanism by which RIIB deficiency
(B) The cumulative incidence of proteinuria (.100 mg/dl) was calcu-results in autoimmunity is shown to be dependent on
lated for the animals described in (A).the loss of peripheral tolerance by RIIB-deficient B cells
in the B6 background.
had life spans comparable to their wild-type littermates;
Results 22 out of 45 (48%) RIIB2/2B6 mice died by 9 months of
age, while none of the 35 RIIB2/2BALB died by the same
age (Figure 1A). Similar results were observed in miceStrain-Dependent Fatal Glomerulonephritis
in FcgRIIB2/2 Mice that had been backcrossed for 12 generations (data not
shown). The most likely cause of death was renal failure,FcgRIIB-deficient mice initially obtained in our labora-
tory on a hybrid Sv129/C57BL/6 background displayed since 40% of the RIIB2/2B6 had high levels of proteinuria
by 5 months of age and 90% of them were proteinuricno abnormalities in either development, life-span, or im-
munological status. In particular, autoantibodies were by 9 months of age (Figure 1B). None of the RIIB2/2BALB
developed proteinuria nor did any wild-type (WT) B6 ornot detected, nor was there evidence of spontaneous
autoimmune disease. Since loss of this inhibitory recep- BALB/c housed under the same conditions (Table 1). In
addition, RIIB2/2B6 mice were anemic, with an averagetor has been shown to result in hyperresponsive B and
myeloid cells, it might be anticipated that autoimmunity hematocrit of 34% at 8 months of age versus the normal
50% observed in both RIIB2/2BALB and WT B6 (Table1).might develop in these animals, as has been observed
in other strains deficient in inhibitory molecules, such Pathological examination of affected animals revealed
that 8-month-old RIIB2/2B6 mice suffered from a severeas CD22, PD-1, Lyn, or SHP-1 (Hibbs et al., 1995; Shultz
et al., 1997; Nishimura et al., 1999; O'Keefe et al., 1999). multiorgan inflammatory disease. Histological analysis
of the lungs and kidneys revealed systemic vasculitis,The absence of autoantibody production or spontane-
ous autoimmune disease suggested that additional ge- with inflammatory cell infiltration. The kidney displayed
evidence of glomerulonephritis consistent with exten-netic or environmental factors might be necessary to
trigger autoimmunity in these susceptible animals. To sive glomerular sclerosis, hypercellularity, and mesan-
gial thickening, indicative of an ongoing, chronic inflam-investigate the contribution of genetic background and
modifier loci to the development of autoimmunity, the matory disease (Figure 2). IgG deposition in glomeruli
was also detected in RIIB2/2B6 mice but not in RIIB2/2129/B6/FcgRIIB2/2 strain was backcrossed for 12 gener-
ations into both BALB/c and C57BL/6 backgrounds. Be- BALB/c (Figure 2). These findings are compatible with
the development of immune complex-mediated glomer-ginning with the seventh generation backcross, C57BL/
6/FcgRIIB2/2 (RIIB2/2B6) animals showed signs of dis- ulonephritis in RIIB2/2B6 animals. Vasculitis, with inflam-
matory cell infiltration, was also observed in salivarytress (e.g., hunched posture, edema, dehydration, re-
duced weight) and reduced viability. In contrast, BALB/ glands, pancreas, liver, tongue, and muscle. In addition,
RIIB2/2B6 mice were profoundly splenomeglic (Table 1)c/FcgRIIB2/2 (RIIB2/2BALB) mice appeared healthy and
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Table 1. Pathology of FcgRII2/2 Mice
WT C57BL/6 FcgRII2/2 C57BL/6 FcgRII2/2 BALB/c
Incidence of proteinuria 0/20 (0%) 41/45 (91%) 0/35 (0%)
Hematocrit (%) 50.0 6 1.2 34.3 6 4.3 52.5 6 1.9
Kidney score (1±4)a 1.0 6 0.8 3.9 6 0.3 0.1 6 0.3
Spleen size (mg) 112 6 16 324 6 120 120 6 17
Spleen cell populations:
Percentage of B2201 cells 55 6 4.2 59 6 5.6 57.6 6 4.0
Percentage of IgMlowIgDlow B cells 5.8 6 0.9 18.6 6 7.1 6.2 6 0.9
IgG-producing B cells (Elispots/106 cells) 72 6 34 511 6 380 35 6 16
CD41/CD81 ratio 2.0 6 0.6 4.3 6 0.4 2.5 6 0.5
Percentage of CD691 CD4 cells 25.5 6 7.8 49.1 6 3.8 19.5 6 0.7
a Scores were obtained by blindly analyzing 10 different hematoxylin-eosin-stained kidney sections with at least 15 glomeruli in each. Glomerular
hypercellularity was graded on a 0±4 scale in which 0 5 no involvement and grades 1±4 5 ,20%, 20%±40%, 40%±80%, and .80% abnormal
glomeruli, respectively.
Values are averages of at least ten 8- to 10-month-old mice per group.
and displayed diffuse lymphoadenopathy. Histological not shown), indicating a state of chronic immune stimu-
lation. These data suggested that RIIB2/2B6 mice devel-examination of the spleen revealed normal architecture
with abundant germinal centers and plasma cells (data oped a spontaneous and fatal glomerulonephritis with
Figure 2. RIIB2/2B6 Mice Develop Immune Complex Glomerulonephritis and Vasculitis
Lung (A-C) and kidney (D-L) sections were stained with hematoxylin-eosin (A-I) or for immune complex deposition in kidney with FITC-anti
mouse IgG (J-L). Only RIIB2/2B6 animals display significant disease and the presence of immune complex deposition in glomeruli. RIIB2/2B6
kidney sections presented abundant protein deposits as well. Magnifications are as noted, demonstrating the hypercellularity and hypertrophy
present in RIIB2/2B6 glomeruli. The figure is representative of most of the glomeruli observed in at least eight mice per group.
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Figure 3. Activated Phenotype of Lympho-
cytes in Aged RIIB2/2B6 Mice
Splenocytes from RIIB2/2 mice were analyzed
by staining with the indicated antibodies and
flow cytometry for 2-month-old and 8-month-
old animals. The boxed regions indicate the
populations that display differences in the
aged RIIB2/2B6 animals, indicative of chronic
lymphoid activation. Similar studies were per-
formed with bone marrow and peripheral
cells, with similar conclusions.
hallmarks of an autoimmune disease, which was contin- differences could be detected in the young RIIB2/2B6
or BALB mice. The pattern of lymphocyte developmentgent upon genetic components from the C57BL/6 back-
ground. The sensitized RIIB2/2 background required ge- shifted in the older, autoimmune animals in a manner
consistent with the presence of chronically stimulatednetic modification from the host background to trigger
the spontaneous disease described above. lymphocytes that are capable of mutual activation.
FcgRIIB2/2 B6 Mice Produce High LevelsActivated Phenotype of Lymphocytes Correlates
with Disease in Aged RIIB2/2B6 Mice of Anti-Nuclear Antibodies
Immune-complex glomerulonephritis has been stronglyThe differences observed in susceptibility to disease
development in the RIIB2/2B6 as compared to the associated with the presence of anti-nuclear antibodies
in numerous animal models of autoimmune disease andRIIB2/2BALB could not be explained by differences in
lymphocyte development in these two strains. We ana- in human lupus (Harley et al., 1998; Wakeland et al.,
1999). Accordingly, anti-nuclear antibody (ANA) testslyzed the lymphocyte populations of spleen (Figure 3)
and bone marrow (data not shown) of 2-month-old mice on sera from 8- to 9-month-old RIIB2/2B6 mice were
performed. RIIB2/2B6 mice showed positive homoge-of each background by flow cytometry and did not de-
tect any significant differences in presence of develop- neous nuclear staining of Hep-2 cells, with titers above
1:1000 in most cases. In contrast, sera from age-mental markers (B220, CD21, CD23, CD24 [HAS], CD44,
IgM, IgD, CD3, Thy-1, CD4, CD8, CD69, CD62L, B7.2, matched WT B6 or RIIB2/2BALB/c were negative in this
assay (Figure 4A). The type of homogeneous nuclearand B7.1). As the mice aged, we could observe an acti-
vated phenotype in both T and B cells in the RIIB2/2B6 staining observed with RIIB2/2B6 sera is similar to the
pattern that has been described for a congenic B6 strainmice but not in RIIB2/2BALB. Total numbers of B and
T cells increased, but the proportion of T and B cells containing an interval derived from chromosome 1 of
the autoimmune strain NZM2410 (Sle1) (Mohan et al.,remained unchanged (Table 1). We detected an increase
in the IgMlowIgDlowCD24null B cell population, a surface 1998). In Sle1.B6 mice, positive ANA staining correlates
with selective antibody reactivity to H2A/H2B/DNA sub-phenotype that correlates with the presence of IgG-
producing mature B cells as detected by Elispot assays nucleosomes. Since the Sle1 interval maps to the same
chromosomal region of chromosome 1 as the FcgRIIB(Table 1). In the T cell compartment, 8-month-old
RIIB2/2B6 mice showed an increase in CD41 cells rela- gene, we determined whether RIIB2/2B6 displayed this
same, restricted specificity. IgG titers against dsDNA,tive to CD81 cells. CD4 cells from RIIB2/2B6 spleens also
expressed high levels of the activation marker CD69, dsDNA/H2A/2B, and dsDNA/H1 were determined and
compared to sera obtained from 12-month-old Sle1.B6and some of them had also lost Thy-1 expression, typical
of germinal center T cells (Figure 3). Other T cell activa- animals. The same specificity of antibody recognition
for DNA/histone complexes was observed in RIIB2/2B6tion markers such as CD44 were also found to be ele-
vated (data not shown). In summary, no developmental sera, although at considerably higher titers than that
Autoimmune Disease in FcgRIIB-Deficient Mice
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Figure 4. Anti-Nuclear Antibodies in RIIB2/2B6
Mice
(A) Immunofluorescence staining of Hep-2
human epithelial cells. Sera from 8-month-
old (RIIB2/2 and NZB/W) or 12-month-old
(SleI and WT B6) animals, at a dilution of
1:200, were used to coat Hep-2 slides. Bound
IgG was detected with FITC-anti mouse IgG.
RIIB2/2B6 and Sle1.B6 display diffuse nuclear
staining; B/W sera generate a speckled nu-
clear staining with some cytoplasmic staining
as well.
(B) ELISA titration of IgG antibodies to dsDNA
alone (middle column), dsDNA complexed
with histone 1 (H1/DNA, front column), or
dsDNA complexed with a mix of histone 2A
and 2B (H2A/H2B/DNA, back column) at the
indicated age as compared to Sle1.B6 and
B/W. Values are averages of at least 12 mice
per group.
(C) Cumulative incidence of anti-chromatin
antibodies in RIIB2/2B6 (n 5 45) and RIIB2/2
BALB (n 5 35) mice. The graph indicates the
proportion of mice that were positive by
ELISA test for H2A/H2B/DNA autoantibodies
as indicated above. Sera were considered
positive when they were in excess of two
standard deviations above the mean level
found in WT B6 serum.
observed in SleI.B6 mice (Figure 4B). Anti-chromatin age (Figure 4C). In striking contrast, none of the RIIB2/2
BALB/c mice developed significant levels of anti-chro-autoantibodies appear in RIIB2/2B6 mice as early as 4±5
months and progressively increase in titer as the animals matin antibodies. This complete penetrance of the anti-
chromatin trait was exploited to determine the pattern ofage. Autoantibodies to other common autoantigens,
such as cardiolipin, myeloperoxidase, or Sm antigen,
were not routinely observed, indicating that the appear-
Table 2. Autoantibody Specificity in the Sera of FcgRII-Deficientance of anti-chromatin autoantibodies results from a
and Other Autoimmune Micespecific loss of tolerance to nuclear antigens and not
a generalized autoreactivity (Table 2). RIIB2/2B6 mice Antigen FcgRIIB2/2 B6 Slel B6 NZB/W
developed autoantibodies of multiple IgG subclasses
dsDNA 28/34 (82%) 2/10 (20%) 1a
including IgG2a but not IgG3. The autoantibody titers dsDNA 1 H2A/2B 33/34 (97%) 7/10 (70%) 1
were in many cases of a comparable titer to that found Cardiolipin 3/34 (8.8%) 0/10 (0%) 1
in sera from well-studied autoimmune mice such as Myeloperoxidase 6/34 (17.6%) 0/10 (0%) 1
MRL/lpr or NZB/W. Collagen IV 1/34 (2.9%) 0/10 (0%) 1
The penetrance of the anti-H2A/H2B/DNA antibody
a Two different pools of sera from six mice were tested.
trait was complete in RIIB2/2B6 mice by 7 months of
Immunity
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Figure 5. Anti-Chromatin Antibodies in Bone
Marrow Reconstituted Mice
Irradiated 6-week-old Rag12/2 (300 rads) or
IgH-62/2 (900 rads) mice were reconstituted
with 5 3 106 RIIB2/2B6 or WT B6 bone marrow
cells purified from a pool of 1-month-old
mice. Sera from reconstituted mice were ob-
tained monthly starting 3 months after the
transfer.
(A) IgG anti-chromatin antibodies were de-
tected by ELISA on H2A/H2B/DNA plates as
in Figure 4. Each circle represents a single
mouse. The dotted line represents the value
of two standard deviations above the mean
level found in WT B6 serum.
(B) FACS analysis of cell populations with an
FcgRIIB-specific mAb (antiLy17.2) (Schiller et
al., 2000).
inheritance of the background modifier loci in these two for RIIB expression, while RIIB1/1 cells dominated the
myeloid compartment, indicating that the transfer of thestrains. In a preliminary cross of RIIB2/2B6 to RIIB2/2
BALB mice, the F1 animals obtained did not develop autoimmune phenotype was dependent on deficiency
of RIIB on B cells and not T or myeloid cells. Animalsautoantibodies by 6 months of age (data not shown),
indicating the likelihood that a C57BL/6 background reconstituted with RIIB-deficient bone marrow devel-
oped proteinuria 5 months after the transfer, indicatingcontributes recessive susceptibility alleles that exacer-
bate the onset of autoimmune disease. that the disease is fully transferable, dependent on B
cells, and that the level and specificity of autoantibodies
in these mice is sufficient to induce glomerulonephritisAutoimmunity in RIIB2/2 B6 Can Be Transferred
without requiring the presence of RIIB2/2 myeloid cellsby Bone Marrow
in the recipient.FcgRIIB receptor is expressed in B and myeloid cell
lineages but not T cells and has been shown to modulate
both humoral and effector responses (Takai et al., 1996).
DiscussionThe disease observed in RIIB2/2B6 mice thus could be
due to either lack of B cell regulation or an increase in
myeloid effector cell response, or both. In an attempt The results described in this study reveal the potential
of the inhibitory FcgRIIB gene to contribute to the main-to delineate the cellular components that contribute to
the development of this autoimmune disease, we per- tenance of tolerance and protection from autoimmune
disease. The role of B cell inhibitory molecules like CD22,formed bone marrow transfers from asymptomatic
1-month-old RIIB2/2B6 mice into irradiated 6-week-old Lyn, or SHP-1 to the maintenance of tolerance has been
deduced by the characterization of mouse strains defi-Rag12/2B6 or IgH2/2B6 mice. The reconstituted animals
were characterized for the presence of autoantibodies cient in these molecules (Hibbs et al., 1995; Shultz et al.,
1997; O'Keefe et al., 1999). Deficiency of CD22 results in(Figure 5A) and for the FcRIIB phenotype of the reconsti-
tuted animals (Figure 5B). Anti-chromatin antibodies autoimmunity in a strain-independent manner, but it
does not result in the development of autoimmune dis-could be detected in sera from the reconstituted mice
as early as 3 months after the transfer of RIIB-deficient ease. Lyn or SHP-1 deficiencies are pleiotropic, resulting
in autoimmunity and development of autoimmune dis-marrow (Figure 5A). The B cell compartment of animals
reconstituted with RIIB2/2B6 bone marrow was negative eases. In contrast, FcgRIIB deficiency results in both
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autoimmunity and autoimmune disease only when modi- Bcl2, all show autoimmune disease only when on the
fied by specific genetic backgrounds. These different C57BL/6 background (Botto et al., 1998; Nishimura et
phenotypes highlight the intrinsic differences in the al., 1999; Strasser et al., 1991). Thus, the C57BL/6 mouse
functions of inhibitory receptors like CD22 and RIIB. strain, which is normally considered disease free and
CD22 inhibits BCR signaling by constitutively associat- innocuous in genetic analyses, can nevertheless con-
ing with the BCR, gating its ability to become activated tribute certain loci that predispose to autoimmunity. The
(Doody et al., 1995). In the absence of CD22, B cells causes for these strain differences in susceptibility to
are hyperresponsive to any stimulus that the BCR may disease are currently unknown, but some candidates
encounter, suggesting that CD22 may act both centrally are the reduced levels of complement in serum or the
and peripherally in maintaining tolerance (O'Keefe et al., bias to a TH1 response in B6 animals (Afonso et al.,
1996; Otipoby et al., 1996; Sato et al., 1996). RIIB only 1994).
associates with the BCR upon cross-linking by immune FcgRIIB thus meets the criteria for a susceptibility
complexes containing antigen with sufficient affinity for factor in the development of systemic autoimmune dis-
the BCR to promote its activation. This condition is only ease, contributing in a combinatorial fashion through
met in the specialized microanatomic structures found the presence of interacting genetic or environmental
in the lymphoid follicles, where immune complex con- factors to the emergence of disease. Its potential role
centration is sufficiently high to permit interaction with in the development of human lupus can now be ad-
the low-affinity RIIB receptor. It is possible, therefore, dressed to determine if specific alleles or, more likely,
that RIIB may function to maintain tolerance in the pe- levels of expression of this inhibitory receptor correlate
riphery, gating BCR activation and deleting low-affinity, with disease susceptibility or severity.
autoreactive cells that might arise during somatic hyper-
mutation. Experimental Procedures
This restricted function of RIIB further explains the
requirement for genetic modifiers for the emergence of Mice
autoimmunity in mice deficient in this receptor. Autoim- The construction of FcgRII-deficient mice was described in Takai
et al., 1996. These mice were originally constructed on a 129Sv/B6munity appears when multiple immunological pathways
hybrid background and were subsequently backcrossed intoare perturbed. In general, single gene knockouts that
BALB/c and C57BL/6 backgrounds for 12 generations. RIIB2/2B6result in autoimmunity have pleiotropic effects on anti-
N7 mice were used for the characterization of the autoimmune pa-gen presentation as well as B and T cell function. Spe-
thology. RIIB2/2B6 N12 mice were used for the bone marrow transfercific genetic backgrounds may provide the additional
experiments as well as for the B6/BALB F1 crosses and FACS analy-coactivating components necessary to the development
sis. Mice were backcrossed at Taconic Farms and maintained atof autoimmune disease. The nature of these genetic
the Rockefeller University animal facility. Rag12/2B6 and IgH-62/2
factors that influence RIIB function is currently unknown, B6 (mMT) animals were purchased from the Jackson Laboratories.
although some insight can be gained based on com-
parisons to other autoimmune strains that display epis- Pathology
tasis. The MHC locus has been demonstrated to be Kidneys, lungs, and various other tissues were fixed with 10% for-
involved in the susceptibility to autoimmunity in both malin in PBS and embedded in paraffin. Sections were stained with
the NZBxNZW F1 and NOD mouse strains (McDevitt, hematoxylin and eosin. To assay for immune complex deposition,
1998; Vyse et al., 1998; Ibnou-Zekri et al., 1999). In the kidneys were embedded in Tissue-Tek OCT compound and snap
frozen. Sections (4 mm) were air-dried, fixed with cold acetone,case of RIIB, however, MHC alone cannot account for
and stained with fluorencein-conjugated anti-mouse IgG (Sigma).the requirement of the B6 background to the develop-
Proteinuria was determined with Chemistrip 2GP dip sticks for uri-ment of autoimmunity, since the 129 strain shares the
nalysis (Roche). Mice were considered positive when at least 100same H-2 background with B6, yet RIIB deficiency on
mg/dL protein was detected in urine. Hematocrit was determinedthe 129 background is phenotypically normal. Segrega-
by centrifugation of blood-filled heparinized microcapillary tubestion of the B/W loci through the use of congenic strains
(Fisher).bearing intervals from NZM2410 has revealed contribu-
tions from the MHC locus as well as regions on chromo-
Assays for Autoantibodies
somes 1 and 7 (Morel et al., 1997). The chromosome 1 Sera were collected monthly and assayed for the presence of anti-
interval is particularly intriguing since B6 mice with this dsDNA, anti H1-DNA, and anti-H2A/2B-DNA IgG antibodies by
interval develop autoimmunity with features quite similar ELISA, as described by Mohan et al., 1999. Briefly, Immulon II plates
to the RIIB2/2B6 strain described here, including B cell (Dynatech) precoated with BSA were coated with 50 mg/ml calf
hyperresponsiveness and the loss of tolerance to nu- dsDNA (Sigma) and postcoated with 10 mg/ml of either histone H1
clear antigens, in particular, H1, H2A ,and H2B DNA com- or a mixture of histones H2A/H2B (Boehringer Mannheim).
Anti-nuclear antibodies tests (ANAs) were performed on Hep-2plexes (Mohan et al., 1998). However, unlike RIIB2/2B6
12-well slides (Bion) stained with mouse serum at various dilutionsmice, Sle1.B6 have a delayed onset of autoantibody
for 30 min followed by fluorencein-conjugated anti-mouse IgG (Fabproduction, weaker penetrance, and lower titers of anti-
specific, Sigma) for 10 min. For the stainings presented in Figure 4,bodies. In addition, Sle1.B6 do not develop autoimmune
sera were diluted 1:200.glomerulonephritis, requiring contributions from the
Sle2 and Sle3 loci to manifest disease (Mohan et al.,
Elispots1999). These data suggest that Sle1 and FcRIIB may be
Antibody secretion by splenocytes was measured by spot ELISA.functionally linked, as might occur if Sle1 contributed
Serial dilutions of erythrocyte-free splenocytes starting at 2 3 106/to the regulation of RIIB expression or signaling. Demon-
ml in RPMI 1640 medium containing 1% albumin were added to
strating the precise relationship between Sle1 and RIIB 96-well Immulon 2 plates coated with goat anti-mouse Ig (H1L)
is currently under investigation. (Southern Biotechnology Associates). After 8 hr at 378C, plates were
In addition to FcgRIIB, other single gene defects have washed with PBS-Tween-BSA and incubated for 2 hr with alkaline
been reported to cause autoimmune disease in a back- phosphatase-conjugated anti-mouse IgG (Southern Biotechnology
ground-specific manner. Deficiencies in C1q or the in- Associates) and developed with 5-bromo-4-chloro-indoylphosphate
(Sigma) in 0.6% agarose/ 0.1 M Tris base.hibitory molecule PD-1, or transgenic expression of
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Bone Marrow Transfers Genetic dissection of SLE pathogenesis. Sle1 on murine chromo-
some 1 leads to a selective loss of tolerance to H2A/H2B/DNASix-week-old B6 Rag12/2 or B6 IgH-62/2 host mice were placed on
neomycin (0.2% w/v) treated water for 1 week before cell transfer. subnucleosomes. J. Clin. Invest. 101, 1362-1372.
Twelve hours before the transfer, the mice received 300 rads Mohan, C., Morel, L., Yang, P., Watanabe, H., Croker, B., Gilkeson,
(Rag12/2) or 900 rads (IgH-62/2) of g-irradiation in a Gamma-cell 40 G., and Wakeland, E.K. (1999). Genetic dissection of lupus patho-
137Cs apparatus. Bone marrow cells were prepared from the femora genesis: a recipe for nephrophilic autoantibodies. J. Clin. Invest.
of 1-month-old B6 WT or RIIB2/2 mice as indicated. Mice received 103, 1685-1695.
107 cells in 0.2 ml HBSS by tail vein injection. Starting 3 months
Morel, L., Mohan, C., Yu, Y., Croker, B.P., Tian, N., Deng, A., and
after the transfer, mice were bled monthly to detect anti-chromatin
Wakeland, E.K. (1997). Functional dissection of systemic lupus ery-
antibodies and tested for proteinuria as described above. Peritoneal
thematosus using congenic mouse strains. J. Immunol. 158, 6019-
cells were extracted 6 months after the transfer and stained for
6028.
FACS analysis with FITC-labeled F4-80 macrophage-specific anti-
Nakamura, A., Yuasa, T., Ujike, A., Ono, M., Nukiwa, T., Ravetch, J.V.,body (Serotec) and biotin-labeled anti-Ly17.2 antibody (Schiller et
and Takai, T. (2000). FcgRIIB-deficient mice develop Goodpasture'sal., 2000) plus cychrome-labeled streptavidin.
syndrome upon immunization with type IV collagen. J. Exp. Med.
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